Tag: https://www.bio.org/events/bio-international-convention
Connecting Investors and Patient Advocacy Groups: An Overview of Funding New Therapies source
Policy Outlook: Understanding the Environment for Pricing and Access to Medicines During an Election Year. source
AI within Biopharma: Separating Value from Hype source
The Next Frontier for Metabolic and Obesity Treatments. source
Congressman Drew Ferguson (R-GA) discusses AMR and the PASTEUR Act with Dr. Stephen Schondelmeyer, Director of the PRIME Institute, University of Minnesota’s College of Pharmacy at the House Ways & Means Committee Hearing on Examining Chronic Drug Shortages in the United States. (Feb. 6, 2024) source
The House Committee on Oversight and Accountability held a markup on a series of legislation including H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act. In opening remarks on H.R.6283, Chair James Comer (R-KY) spoke to the importance of increasing transparency among the role of pharmacy benefit managers (PBMs) specifically within the Federal Employees […]
BIO Board member Eddie J. Sullivan testifies at the House Ways and Means Trade Subcommittee about the impact an expanded IP waiver would have on innovative biotechs like SAb Biotherapeutics. Bio.News: https://bio.news/international/wto-ip-waiver-biotech-innovation-sab-biotherapeutics-capitol-hill/ (Feb. 7, 2024) source
Senate HELP Committee hearing, “Why Does the United States Pay, by Far, the Highest Prices in the World for Prescription Drugs?” focusing on the role of manufacturers in drug pricing. Sen. Cassidy says that Sen. Sanders’ goal for the hearing was to blame drug manufacturers for high drug prices instead of focusing on perverse incentives […]